- Details
- Hala Borno joins Alicia Morgans and discusses a recent viewpoint article in JAMA Oncology titled “The Ethics of Delivering Precision Medicine—Pretest Counseling and Somatic Genomic Testing.” In the new era of precision medicine in cancer treatment, many clinicians use patient tumor genomic (somatic) data as part of routine clinical practice. Dr. Borno shares insights into Pretest Counseling in an...
|
- Details
- Together with Alicia Morgans, Maria Carlo delves into the topic of germline testing for patients with genitourinary malignancies. In a more non-traditional approach to investigating the effects of DNA repair defects on prostate and bladder cancer, Carlo factors in not only oncological outcomes, but also psychological outcomes of her clinical trials. Biographies: Maria Carlo, MD, Medical Oncologist...
|
- Details
- Brian Helfand presents the use of genomics today to personalize the treatment of men with prostate cancer and the different models on how to implement this testing in your clinic. There are not enough genetic counselors throughout the country to answer everyone's needs, so it is important as a urologist to start initiating these conversations with patients. Biographies: Brian T. Helfand, M.D., Ph....
|
- Details
- Colin Pritchard joins Charles Ryan at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) where they discuss PARP inhibitor data that came out of the 2019 ESMO meeting including the PROfound study data, rucaparib in TRITON2, and niraparib in the GALAHAD study and focusing on monoallelic versus biallelic BRCA2 alterations. Biographies: Colin C Pritchard, M.D., Ph.D. is the Dire...
|
- Details
- Elena Castro, MD joins Alicia Morgans, MD, MPH at the 2019 Prostate Cancer Foundation Retreat (PCF 2019) to discuss PROREPAIR-B. This was an academic prospective observational study evaluating the prevalence and impact of germline mutations in BRCA1, BRCA2, ATM and PALB2 on metastatic castration-resistance prostate cancer (mCRPC) outcomes. Biographies: Elena Castro, MD, Prostate Cancer and Genitou...
|
- Details
- At the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019), Joaquin Mateo, Principal Investigator, and Translational Scientist at the Vall d'Hebron hospital in Barcelona joined Charles Ryan to discuss how PARP inhibitors are being integrated into the standard of care for prostate cancer, pivotal studies that are reporting and ongoing with PARP inhibitors, and important aspect of t...
|
- Details
- Mary-Ellen Taplin, Professor of Medicine Harvard Medical School and a GU Medical Oncologist at the Dana-Farber Cancer Institute, joins Alicia Morgans at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) to speak about germline testing. They discuss what is required in implementing genetic testing into clinical practice and ways of disseminating the data to perform germline t...
|
- Details
- Colin Pritchard from the University of Washington joins Charles Ryan at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) to speak about his recent editorial that was published in Nature that advocates for a renaming of the genetic syndrome that we commonly call BRCA2 mutation or the "breast cancer gene". They're named the breast cancer genes but it is limiting because prost...
|
- Details
- In this conversation, Alicia Morgans and Rosalind Eeles discuss how patients should be selected for genetic counseling and testing. This discussion highlights several important questions including: What is the spectrum of genetic predisposition that we currently know? How should we use this? Who should be tested? Are there international discrepancies in the guidelines? How do we manage men who are...
|
- Details
- During the Molecular Biomarkers and Novel Imaging in Advanced Prostate Cancer session at the Advanced Prostate Cancer Consensus Conference (APCCC 2019), Dr. Rosalind Eeles discussed how patients should be selected for genetic counseling and testing. She highlights several key points for clinicians to consider when thinking through how we should think about which men should be tested for genetic ab...
|
